TSX runs higher on rate cut expectations
Investing.com - Needham has initiated coverage on Oculis Holding AG (NASDAQ:OCS) with a Buy rating and a price target of $36.00, citing the company’s portfolio of late-stage ophthalmology assets. Currently trading at $17.53 with a market cap of $958 million, Oculis has garnered strong analyst support, with targets ranging from $28 to $50.
The research firm highlighted OCS-01, Oculis’ lead asset, which aims to become the first non-invasive therapy for diabetic macular edema (DME). According to Needham, this treatment could address patients with inadequate responses to anti-VEGF therapies and potentially expand the market to early-stage DME patients who typically remain untreated. InvestingPro data shows the company maintains a strong financial position with more cash than debt and a healthy current ratio of 4.55x.
Needham also noted OCS-02, which offers an anti-TNF biological mechanism of action for dry-eye disease delivered via eye drop, utilizing a precision medicine approach to reduce development risk. The firm mentioned OCS-05 as well, which has demonstrated neuroprotective benefits that could address various ophthalmic and neuro-ophthalmic indications.
The research firm described Oculis as an "under-the-radar story" that is approaching a data-rich period in early 2026, which could potentially drive significant shareholder value.
Oculis’ portfolio of "highly-differentiated late-stage assets" addresses unmet needs across various eye disease indications, according to Needham’s analysis of the company’s potential market position.
In other recent news, Oculis Holding has seen several updates that may interest investors. The company reported its second-quarter 2025 financial results, noting grant income of CHF 0.3 million and a net loss of CHF 25.4 million, or CHF 0.49 per share. Following these results, H.C. Wainwright raised its price target for Oculis Holding to $33 from $32, maintaining a Buy rating. Additionally, Stifel reiterated its Buy rating with a $35 price target, emphasizing progress in Oculis’ late-stage pipeline, particularly the development of OCS-01 and OCS-05/privosegtor. Leerink Partners also raised its price target for Oculis Holding significantly, from $22 to $50, while maintaining an Outperform rating. This adjustment came after discussions with physicians and insights from a recent analyst meeting, highlighting the potential of privosegtor (OCS-05) in preventing optic nerve degeneration. These developments reflect growing optimism among analysts regarding Oculis’ future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.